Study uncovers how chronic kidney disease impacts glucose and glycemic control (SACRAMENTO) A new collaborative study from researchers at UC Davis Health and the UC Davis School of Veterinary Medicine reveals how complications from chronic kidney disease (CKD) are linked to problems in the metabolic system
Practical trade-offs include gastrointestinal side effects and the fact that most GLP-1s are injections, but overall, theyre both safe and effective
Frequently Asked Questions (FAQs) Does hunger on semaglutide mean it's not working
GLP-1 Receptor Agonist Market Segmentation By Product Outlook (Revenue, USD Billion, 20212034) Ozempic Trulicity Mounjaro Wegovy Rybelsus Saxenda Victoza Zepbound Others By Application Outlook (Revenue, USD Billion, 20212034) Type 2 Diabetes Mellitus Obesity By Route of Administration Outlook (Revenue, USD Billion, 20212034) Parenteral Oral By Distribution Channel Outlook (Revenue, USD Billion, 20212034) Hospital Pharmacies Retail Pharmacies Online Pharmacies By Regional Outlook (Revenue, USD Billion, 20212034) North America US Canada Europe Germany France UK Italy Spain Netherlands Russia Rest of Europe Asia Pacific China Japan India Malaysia South Korea Indonesia Australia Vietnam Rest of Asia Pacific Middle East & Africa Saudi Arabia UAE Israel South Africa Rest of Middle East & Africa Latin America Mexico Brazil Argentina Rest of Latin America GLP-1 Receptor Agonist Market Report Scope Source: Polaris Market Research Analysis GLP-1 Receptor Agonist Market FAQ's The global market size was valued at USD 61.89 billion in 2025 and is projected to grow to USD 257.12 billion by 2034
Xenical was followed by the lower dose, over-the-counter (OTC) orlistat (alli) in 2007
